Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies
Open Access
- 21 November 2016
- journal article
- review article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (3) , 5578-5591
Abstract
Increased mammographic density (MD) has been shown beyond doubt to be a marker for increased breast cancer risk, though the underpinning pathobiology is yet to be fully elucidated. Estrogenic activity exerts a strong influence over MD, which consequently has been observed to change predictably in response to tamoxifen anti-estrogen therapy, although results for other selective estrogen receptor modulators and aromatase inhibitors are less consistent. In both primary and secondary prevention settings, tamoxifen-associated MD changes correlate with successful modulation of risk or outcome, particularly among pre-menopausal women; an observation that supports the potential use of MD change as a surrogate marker where short-term MD changes reflect longer-term anti-estrogen efficacy. Here we summarize endocrine therapy-induced MD changes and attendant outcomes and discuss both the need for outcome surrogates in such therapy, as well as make a case for MD as such a monitoring marker. We then discuss the process and steps required to validate and introduce MD into practice as a predictor or surrogate for endocrine therapy efficacy in preventive and adjuvant breast cancer treatment settings.Keywords
This publication has 102 references indexed in Scilit:
- Change of mammographic density predicts the risk of contralateral breast cancer - a case-control studyBreast Cancer Research, 2013
- Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort studyBreast Cancer Research, 2012
- Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-upThe Lancet Oncology, 2011
- Quantitative Assessment of Mammary Gland Density in Rodents Using Digital Image AnalysisBiological Procedures Online, 2011
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast CancerCancer Prevention Research, 2010
- Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studiesThe Lancet Oncology, 2010
- Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast CancerCancer Epidemiology, Biomarkers & Prevention, 2008
- Fibroblasts in cancerNature Reviews Cancer, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001